Oral Surgery · single question
A patient on zoledronic acid (Zometa) for bone metastasis has medication-related osteonecrosis of the jaw (MRONJ) at Stage 0 (asymptomatic, no necrotic bone visible). What is the most appropriate management?
Show answer and explanation
Correct answer: B. Wait, monitor, and supportive care only
B) Wait and monitor (conservative management) — CORRECT for Stage 0.
MRONJ staging (AAOMS): Stage 0 = no clinical evidence of necrotic bone but non-specific symptoms/radiographic changes. Management: conservative/non-surgical — antimicrobial rinses (chlorhexidine), patient education, pain management, monitor. Surgical intervention is reserved for Stages 2–3.
A) Implants: Absolutely contraindicated in patients on high-dose IV bisphosphonates — extreme MRONJ risk.
C) Surgical resection: Stage 2 (exposed/necrotic bone with pain and/or infection) or Stage 3 management — too aggressive for Stage 0.
D) Discontinuing zoledronic acid: Decision made by the oncologist; cannot be done without medical consultation — and the drug's effect persists in bone for years regardless.
MRONJ staging (AAOMS): Stage 0 = no clinical evidence of necrotic bone but non-specific symptoms/radiographic changes. Management: conservative/non-surgical — antimicrobial rinses (chlorhexidine), patient education, pain management, monitor. Surgical intervention is reserved for Stages 2–3.
A) Implants: Absolutely contraindicated in patients on high-dose IV bisphosphonates — extreme MRONJ risk.
C) Surgical resection: Stage 2 (exposed/necrotic bone with pain and/or infection) or Stage 3 management — too aggressive for Stage 0.
D) Discontinuing zoledronic acid: Decision made by the oncologist; cannot be done without medical consultation — and the drug's effect persists in bone for years regardless.